Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading
cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive …

The human gut microbiome is a huge microbial community that plays an irreplaceable role
in human life. With the further development of research, the influence of intestinal flora on …

Dietary nutrients and the gut microbiota are increasingly recognized to cross-regulate and
entrain each other, and thus affect host health and immune-mediated diseases. Here, we …

The metabolic associated fatty liver disease (MAFLD) is a public health challenge, leading to
a global increase in chronic liver disease. The respiratory exposure of silica nanoparticles …

Accumulating evidence over the past decades has revealed an intricate relationship
between dysregulation of cellular metabolism and the progression of atherosclerotic …

Glucose and fructose are closely related simple sugars, but fructose has been associated
more closely with metabolic disease. Until the 1960s, the major dietary source of fructose …

Amino acid dysregulation has emerged as an important driver of disease progression in
various contexts. l-Serine lies at a central node of metabolism, linking carbohydrate …

Nonalcoholic steatohepatitis (NASH) prevalence is rising with no pharmacotherapy
approved. A major hurdle in NASH drug development is the poor translatability of preclinical …

Nonalcoholic steatohepatitis (NASH) has been linked with the gut-liver axis. Here, we
investigate the potential for repurposing disulfiram (DSF), a drug commonly used to treat …

Mitochondrial dysfunction and oxidative stress-mediated inflammasome activation play
critical roles in the pathogenesis of the non-alcoholic fatty liver disease (NAFLD). Non …